439 related articles for article (PubMed ID: 33872981)
21. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
22. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.
Wang W; Gu X; Si J; Pu X; Wang L; Chen H; Xu C; Zhang X; Yuan H; Lou G; Shao L; Zhang G; Song Z
Genes Chromosomes Cancer; 2022 Sep; 61(9):530-541. PubMed ID: 35396765
[TBL] [Abstract][Full Text] [Related]
25. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Li S; Zhang C; Pang G; Wang P
Front Immunol; 2020; 11():603157. PubMed ID: 33178229
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
28. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
29. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
30. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
Prelaj A; Tay R; Ferrara R; Chaput N; Besse B; Califano R
Eur J Cancer; 2019 Jan; 106():144-159. PubMed ID: 30528799
[TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
32. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
Hastings K; Yu HA; Wei W; Sanchez-Vega F; DeVeaux M; Choi J; Rizvi H; Lisberg A; Truini A; Lydon CA; Liu Z; Henick BS; Wurtz A; Cai G; Plodkowski AJ; Long NM; Halpenny DF; Killam J; Oliva I; Schultz N; Riely GJ; Arcila ME; Ladanyi M; Zelterman D; Herbst RS; Goldberg SB; Awad MM; Garon EB; Gettinger S; Hellmann MD; Politi K
Ann Oncol; 2019 Aug; 30(8):1311-1320. PubMed ID: 31086949
[TBL] [Abstract][Full Text] [Related]
33. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
[TBL] [Abstract][Full Text] [Related]
34. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
35. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Sakai T; Matsumoto S; Ueda Y; Shibata Y; Ikeda T; Nakamura A; Kodani M; Ohashi K; Furuya N; Izumi H; Nosaki K; Umemura S; Zenke Y; Udagawa H; Sugiyama E; Yoh K; Goto K
J Thorac Oncol; 2023 Nov; 18(11):1538-1549. PubMed ID: 37543207
[TBL] [Abstract][Full Text] [Related]
36. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in Advanced Lung Cancer.
Huang J; Reckamp KL
Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]